Strata Skin Sciences, Inc. (SSKN) Sees 52-Week Low


The company is now down by 15.65% percent from yesterday’s close. Company shares are trading at $1.24 well below the 50 day moving average of $1.73 and which is significantly lower than the 200 day moving average of $2.23. The 50 day moving average was down $-0.49 and the 200 day average moved down $-0.99.

Traders are a little more bullish on Strata Skin Sciences, Inc. of late if you evaluate the change in short interest. The company realized a fall in short interest between September 15, 2017 and September 29, 2017 of -10.26%. Short shares decreased from 83,292 to 74,747 over that timeframe. The days to cover decreased to 4.0 and the short interest percentage is 0.03% as of September 29.

STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., launched on October 3, 1997, is a medical technology company. The Company is involved in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company has approximately two distribution channels for phototherapy treatment equipment. The Company places its lasers in a physician’s office or sells its lasers through a distributor or directly to a physician..

Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Guggenheim Capital LLC had bought 91 shares growing its position 0.6%. The value of the investment in SSKN went from $7,000 to $9,000 increasing 28.6% since the last quarter. Goldman Sachs Group Inc divested its ownership by selling 2,781 shares a decrease of 12.8% in the quarter. Goldman Sachs Group Inc controls 19,018 shares with a value of $12,000. The total value of its holdings increased 20.0%.

Morgan Stanley trimmed its position by shedding 1,240 shares a decrease of 92.5% from 12/31/2016 to 03/31/2017. Morgan Stanley owns 100 shares valued at $0. The value of the position overall is down by 100.0%. As of quarter end Sabby Management, LLC had disposed of a total of 473,195 shares trimming its holdings by 66.8%. The value of the company’s investment in Strata Skin Sciences, Inc. increased from $428,000 to $571,000 a change of 33.4% for the reporting period.

As of the last earnings report the EPS was $-2.75 and is estimated to be $-3.14 for the current year with 2,477,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $-0.90 with next year’s EPS anticipated to be $-0.77.